NEUP Stock Moves Higher as Traders Focus on Neuphoria’s Cash Runway
Neuphoria Therapeutics traded at $5.00, up 4.8% in midday Nasdaq action, as biotech stocks rallied. The company reported no license revenue for the March quarter, a $505,063 net loss, and $19.4 million in cash. Neuphoria has halted most operations after an October trial failure and is seeking strategic options. Volume reached 33,745 shares.
